Clinical Trial

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-05; most recent amendment 2025-06-08.
Trial Details
NCT Number NCT06298409
Lead Sponsor Envivo Bio Inc
Conditions Small Intestinal Bacterial Overgrowth
Enrollment 34 participants
Start Date 2024-02-15
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-11